Recombinant Human Claudin-18.2 (CLDN18.2)-Detergent (Active)

Claudin-18.2 represents a gastric-specific tight junction protein that has emerged as a promising target in oncology, particularly for gastric and pancreatic adenocarcinomas where aberrant expression correlates with tumor progression. This full-length isoform A2 construct (aa 1–261) expressed in mammalian cells demonstrates robust antibody binding activity in functional ELISA, achieving an EC50 of 0.46–0.64 ng/mL with an anti-CLDN18.2 recombinant antibody—a quantitative measure that supports its use in antibody development and validation workflows where precise epitope recognition is critical. The mammalian expression system preserves native post-translational modifications and membrane protein topology, providing a suitable basis for cell adhesion assays and tumor metastasis research models that depend on authentic claudin-mediated cell–cell interactions. Supplied with a C-terminal 10×His tag for streamlined purification and immobilization, this protein meets the >80% purity threshold commonly required for functional binding studies and therapeutic antibody screening campaigns.